Home

Parkinsons

"Expert On The Spot: The End of Parkinson's Disease"

 

Do you know someone living with Parkinson's disease? This month's Expert on the Spot focuses on Deep Brain Stimulation (DBS) which is like a brain pacemaker, relieving symptoms and improving the quality of life. PhD Student Adam Zaidel's current research brings him to the surgery room once a week and at the forefront to the fight against Parkinson's. Watch this short clip and submit your questions. Check out the answers in a video with Adam on July 13th.

0
Your rating: None

“Prof. Moussa Youdim -- Neurodegenerative Disease Therapies”

 After 20 years of research, Prof. Moussa Youdim of Technion's Rappaport Faculty of Medicine developed a drug for Parkinson's disease. Prof. Youdim discusses neurodegenerative disease therapies including new breakthrough drugs for the treatment of Alzheimer's disease. His and his colleagues' work continue to help develop drugs that may in the future not only treat these diseases but reverse their effects. Film by the American Technion Society. 

0
Your rating: None

“Dr. Silvia Mandel Discussing Research on Parkinson's and Alzheimer's Diseases”

 The search for treatments for diseases of aging is becoming all the more important as life expectancy continues to increase. Dr. Silvia Mandel of Technion's Faculty of Medicine discusses her work on deciphering the causes of degenerative diseases such as Parkinson's at the molecular level. She works with Prof. Moussa Youdim and Prof. John Finberg, who developed a promising drug to treat Parkinson's disease, Azilect, which has been recently approved by the FDA. 

0
Your rating: None

Play of the Day: Teva Pharmaceuticals

Teva (an Israeli pharmaceutical company) has developed a drug called Azilect. This new drug slows Parkinson’s disease and is the first drug of its kind. In this video, learn about how this new development will work in an economic sense and find out how Teva’s discovery of this breakthrough drug may prove to be a new demand in the pharmaceutical market.  

0
Your rating: None
Syndicate content